



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAME APPLICANT	ATTORNEY DOCKET NO.
07/119,114	11/10/87	BRANCA	Q 4029/3

JON S. SAXE
HOFFMANN-LA ROCHE INC.
340 KINGSLAND STREET
NUTLEY, NJ 07110

EXAMINER	
BRISCOE, JR.	
ART UNIT	PAPER NUMBER
121	B 4

DATE MAILED: 04/19/88

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Responsive to communication filed on _____ This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), _____ days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- Notice of References Cited by Examiner, PTO-892.
- Notice re Patent Drawing, PTO-948.
- Notice of Art Cited by Applicant, PTO-1449
- Notice of informal Patent Application, Form PTO-152
- Information on How to Effect Drawing Changes, PTO-1474
- _____

Part II SUMMARY OF ACTION

1. Claims 1 - 21 are pending in the application.

Of the above, claims _____ are withdrawn from consideration.

2. Claims _____ have been cancelled.

3. Claims _____ are allowed.

4. Claims 1, 2, 5-11, and 14-21 are rejected.

5. Claims 3, 4, and 12-15 are objected to.

6. Claims _____ are subject to restriction or election requirement.

7. This application has been filed with informal drawings which are acceptable for examination purposes until such time as allowable subject matter is indicated.

8. Allowable subject matter having been indicated, formal drawings are required in response to this Office action.

9. The corrected or substitute drawings have been received on _____. These drawings are acceptable;
 not acceptable (see explanation).

10. The proposed drawing correction and/or the proposed additional or substitute sheet(s) of drawings, filed on _____,
has (have) been approved by the examiner. disapproved by the examiner (see explanation).

11. The proposed drawing correction, filed _____, has been approved. disapproved (see explanation). However,
the Patent and Trademark Office no longer makes drawing changes. It is now applicant's responsibility to ensure that the drawings are
corrected. Corrections **MUST** be effected in accordance with the instructions set forth on the attached letter "INFORMATION ON HOW TO
EFFECT DRAWING CHANGES", PTO-1474.

12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received not been received

been filed in parent application, serial no. _____; filed on _____.

13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in
accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

14. Other

Art Unit 121

Claims 1, 2, 5-11, and 16-21 are rejected under 35 U.S.C. 112, first and second paragraphs, as the claimed invention is not described in such full, clear, concise and exact terms as to enable any person skilled in the art to make and use the same, and/or for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "aryl", whether alone or as a part of a substituent group, e.g., "aralkyl", is indefinite and otherwise not adequately supported by the enabling disclosure. "Aryl" is normally construed to read on any aromatic radical and, thus, embraces embodiments that have not been shown by adequate representative examples or otherwise to be Applicants' actual invention. See, *In re Lund et al.*, 153 USPQ 625; and *In re Sus*, 134 USPQ 301. Applicants adequately support "aryl" as "phenyl".

While composition and method claims may use functional language to specify the amount of active ingredient to be used, a claim which recites the amount functionally as "an effective amount" is indefinite since it does not recite the intended effect. See, *Ex parte Dobson*, 165 USPQ 29. "A calcium antagonistic effective amount" is suggested.

Claims 3, 4, and 12-15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication should be directed to Kurt Briscoe at telephone number 703-557-3920.

M. Lee
MARY C. LEE
SUPERVISORY PRIMARY EXAMINER
ART UNIT 121

W.L.